Tunable metal-organic framework compositions and methods thereof
View Patent ↗The present invention relates to a metal-organic framework composition, as well as constructs and methods thereof. In one particular example, the composition provides a platform having an emission signal in the deep red to near-infrared (NIR) region.
1. A metal-organic framework composition comprising a plurality of metal clusters and a plurality of ligands coordinating with the plurality of metal clusters, wherein at least one metal cluster comprises a metal ion, at least one ligand is a monodentate ligand, and at least one ligand is a bidentate ligand,
wherein the plurality of metal clusters and plurality of ligands are characterized by a tetragonal crystal structure,
wherein the at least one metal cluster comprises a hexanuclear cluster,
wherein the metal ion is a rare earth metal ion selected from the group consisting of Eu, Nd, Yb, Y, Tb, La, Ce, Pr, Sm, Gd, Dy, Ho, Er, Tm, and Lu, and
wherein each of the plurality of ligands, independently, comprises a structure of L 1 -R L -L 2 , wherein each of L 1 and L 2 is, independently, a reactive group, and wherein R L is a linker comprising an optionally substituted aryl or an optionally substituted heteroaryl.
2. The composition of claim 1 , wherein each of the plurality of metal clusters comprises a hexanuclear cluster.
3. The composition of claim 1 , wherein the metal ion is selected from the group consisting of Eu, Nd, Yb, Y, and Tb.
4. The composition of claim 1 , wherein the plurality of metal clusters comprises a first metal ion and a second metal ion that is different than the first metal ion, and wherein the plurality of metal clusters comprises a first metal ion having a first coordination geometry and a second metal ion having a second coordination geometry that is different than the first coordinate geometry.
5. The composition of claim 1 , comprising a plurality of monodentate ligands and a plurality of bidentate ligands.
6. The composition of claim 5 , wherein each of the monodentate ligands and the each of the bidentate ligands comprises a structure of L 1 -R L -L 2 , wherein each of L 1 and L 2 is, independently, a reactive group, and wherein R L is a linker.
7. The composition of claim 6 , wherein R L comprises an optionally substituted aryl or an optionally substituted heteroaryl; and wherein each of L 1 and L 2 comprises, independently, carboxyl, heterocyclyl, hydroxyl, an anion thereof, a salt thereof, or an ester thereof.
8. The composition of claim 1 , wherein each of L 1 and L 2 comprises, independently, carboxyl, heterocyclyl, hydroxyl, an anion thereof, a salt thereof, or an ester thereof.
9. A construct comprising:
a metal-organic framework (MOF) composition comprising a plurality of metal clusters and a plurality of ligands coordinating with the plurality of metal clusters, wherein at least one metal cluster comprises a metal ion, at least one ligand is a monodentate ligand, and at least one ligand is a bidentate ligand; and
an outer layer comprising a polymer, a lipid, a lipid layer, an organic matrix, an inorganic matrix, and/or a shell, wherein the outer layer is disposed directly or indirectly on a surface of the MOF composition,
wherein the at least one metal cluster comprises a hexanuclear cluster,
wherein the metal ion is a rare earth metal ion selected from the group consisting of Eu, Nd, Yb, Y, Tb, La, Ce, Pr, Sm, Gd, Dy, Ho, Er, Tm, and Lu, and
wherein each of the plurality of ligands, independently, comprises a structure of L 1 -R L -L 2 , wherein each of L 1 and L 2 is, independently, a reactive group, and wherein R L is a linker comprising an optionally substituted aryl or an optionally substituted heteroaryl.
10. The construct of claim 9 , further comprising:
one or more cargos disposed in proximity to and/or within the MOF composition and/or the outer layer.
11. The construct of claim 9 , wherein the MOF composition is provided as one or more cores, and wherein the outer layer is disposed on an external surface, or a portion thereof, of the one or more cores.
12. A formulation comprising a construct of claim 9 , or a salt or an anhydrate or a solvate thereof, and a pharmaceutically acceptable excipient.
13. The construct of claim 9 , wherein each of the plurality of metal clusters comprises a hexanuclear cluster.
14. The construct of claim 9 , wherein the metal ion is selected from the group consisting of Eu, Nd, Yb, Y, and Tb.
15. The construct of claim 9 , wherein the plurality of metal clusters comprises a first metal ion and a second metal ion that is different than the first metal ion, and wherein the plurality of metal clusters comprises a first metal ion having a first coordination geometry and a second metal ion having a second coordination geometry that is different than the first coordinate geometry.
16. The construct of claim 9 , comprising a plurality of monodentate ligands and a plurality of bidentate ligands.
17. The construct of claim 16 , wherein each of the monodentate ligands and the each of the bidentate ligands comprises the structure of L 1 -R L -L 2 .
18. The construct of claim 9 , wherein each of L 1 and L 2 comprises, independently, carboxyl, heterocyclyl, hydroxyl, an anion thereof, a salt thereof, or an ester thereof.
19. The construct of claim 9 , wherein the plurality of metal clusters and plurality of ligands are characterized by a tetragonal crystal structure.
20. A formulation comprising a metal-organic framework composition comprising a plurality of metal clusters and a plurality of ligands coordinating with the plurality of metal clusters, wherein at least one metal cluster comprises a metal ion, at least one ligand is a monodentate ligand, and at least one ligand is a bidentate ligand,
wherein the plurality of metal clusters and plurality of ligands are characterized by a tetragonal crystal structure,
wherein the at least one metal cluster comprises a hexanuclear cluster,
wherein the metal ion is a rare earth metal ion selected from the group consisting of Eu, Nd, Yb, Y, Tb, La, Ce, Pr, Sm, Gd, Dy, Ho, Er, Tm, and Lu, and
wherein each of the plurality of ligands, independently, comprises a structure of L 1 -R L -L 2 , wherein each of L 1 and L 2 is, independently, a reactive group, and wherein R L is a linker comprising an optionally substituted aryl or an optionally substituted heteroaryl; or a salt or an anhydrate or a solvate thereof,
and a pharmaceutically acceptable excipient.